FY25/26 guidance cut related to demand softness in Curing

hoenle cuts FY 25/26 guidance on persistent Curing weakness; revenue now € 92–95m, EBITDA € 5–6m. Investment case intact; BUY, PT cut to € 14 (prev. € 15).